Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 24, 2012
Reinfection redux
Andrew A Vernon, M Elsa Villarino
The New England Journal of Medicine
|
June 6, 2019
Reply to: "Rifapentine and Isoniazid for Latent Tuberculosis"
Timothy R Sterling, Ruth Moro, M. Elsa Villarino
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 9, 2016
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada
Ruth N Moro, Andrey S Borisov, Jussi Saukkonen, et al.
JAMA Pediatrics
|
January 13, 2015
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid
M Elsa Villarino, Nigel A Scott, Stephen E Weis, et al.
AIDS (London, England)
|
June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons
Timothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Annals of the American Thoracic Society
|
March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatment
Craig M Hales, Charles M Heilig, Richard Chaisson, et al.
The Lancet. Respiratory Medicine
|
March 26, 2023
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis
Nicholas Winters, Robert Belknap, Andrea Benedetti, et al.
Lancet (London, England)
|
September 21, 2002
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
Debra Benator, Mondira Bhattacharya, Lorna Bozeman, et al.
The New England Journal of Medicine
|
December 14, 2011
Three months of rifapentine and isoniazid for latent tuberculosis infection
Timothy R Sterling, M Elsa Villarino, Andrey S Borisov, et al.
Journal of the Pediatric Infectious Diseases Society
|
December 2, 2015
Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection
Marc Weiner, Radojka M Savic, William R Mac Kenzie, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 24, 2012
Reinfection redux
Andrew A Vernon, M Elsa Villarino
The New England Journal of Medicine
|
June 6, 2019
Reply to: "Rifapentine and Isoniazid for Latent Tuberculosis"
Timothy R Sterling, Ruth Moro, M. Elsa Villarino
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 9, 2016
Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada
Ruth N Moro, Andrey S Borisov, Jussi Saukkonen, et al.
JAMA Pediatrics
|
January 13, 2015
Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid
M Elsa Villarino, Nigel A Scott, Stephen E Weis, et al.
AIDS (London, England)
|
June 1, 2016
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons
Timothy R Sterling, Nigel A Scott, Jose M Miro, et al.
Annals of the American Thoracic Society
|
March 20, 2013
The association between symptoms and microbiologically defined response to tuberculosis treatment
Craig M Hales, Charles M Heilig, Richard Chaisson, et al.
The Lancet. Respiratory Medicine
|
March 26, 2023
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis
Nicholas Winters, Robert Belknap, Andrea Benedetti, et al.
Lancet (London, England)
|
September 21, 2002
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
Debra Benator, Mondira Bhattacharya, Lorna Bozeman, et al.
The New England Journal of Medicine
|
December 14, 2011
Three months of rifapentine and isoniazid for latent tuberculosis infection
Timothy R Sterling, M Elsa Villarino, Andrey S Borisov, et al.
Journal of the Pediatric Infectious Diseases Society
|
December 2, 2015
Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection
Marc Weiner, Radojka M Savic, William R Mac Kenzie, et al.
Page
of 2